Toll-like receptors in lupus nephritis by Devarapu, Satish Kumar & Anders, Hans-Joachim
REVIEW Open Access
Toll-like receptors in lupus nephritis
Satish Kumar Devarapu and Hans-Joachim Anders*
Abstract
The pathogenesis of systemic autoimmune diseases such as systemic lupus erythematosus (SLE) is based on the
loss of self-tolerance against ubiquitous autoantigens involving all mechanisms of adaptive immunity. However,
data accumulating over the last decade imply an important role also for numerous elements of innate immunity,
namely the Toll-like receptors in the pathogenesis of SLE. Here we discuss their role in the most common organ
complication of SLE, i.e. lupus nephritis. We summarize experimental and clinical data on the expression and
functional contribution of the Toll-like receptors in immune complex glomerulonephritis, and intrarenal inflammation.
Based on these discoveries Toll-like receptors are evolving as therapeutic targets for the treatment of SLE and lupus
nephritis.
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Background
Toll-like receptors (TLR) have an essential role in innate
immunity during host defense which impacts also on
auto-inflammatory and autoimmune diseases [1]. Once
Tlr-deficient mice became available the hypothesis of
TLRs as boosters of systemic autoimmunity [2] including
disease such as systemic lupus erythematosus (SLE) became
possible. In the first part of this review, we discuss the role
of TLRs in SLE and in the second part their contribution to
intrarenal inflammation in lupus nephritis (LN). Further, we
have also briefly mentioned about TLR role in immune
tolerance break and germinal center formation in the
second part.
Toll-like receptors in systemic autoimmunity upstream to
nephritis
Based on the location of expression, TLRs are classified
into extra-cellular and intra-cellular (Fig. 1).
Extracellular TLRs
Toll-like receptors 2 and 4
TLR-2 and TLR-4 are membrane-bound receptors that
recognize bacterial wall components and endogenous
components of dying cells, so-called damage-associated
molecular patterns (DAMPs) [3, 4]. In C57BL6lpr/lpr mice,
a model of spontaneous autoimmunity, TLR2 or TLR4
deficiency limits the expansion of the marginal zone B cell
compartment and attenuates the levels of antinuclear-
antibodies and rheumatoid factors [5]. However, it should
be noted that C57BL6lpr/lpr mice are a very mild strain in
developing the disease compared with MRL-lpr strain.
Interestingly, anti-nucleosome antibodies are diminished in
the absence of TLR2 but not of TLR4 [5]. Administration of
pristine a natural saturated terpenoid alkane to genetically
intact mice results in the development of hypergammaglo-
bulinaemia with the production of lupus-like autoantibodies
and proliferative glomerulonephritis, with similarities
to human lupus nephritis. However, administration of
the pristine in Tlr4- deficient mice demonstrated a
global decrease in both Th1, IFNγ, and Th17 associated
IL-17A and IL-6 cytokine production. Also, autoantibody
levels of anti-dsDNA and anti-RNP were both decreased
indicating the requirement of TLR4 for the full-blown
autoimmunity [6]. Furthermore, exposing anti-ds DNA
transgenic mice to TLR4 agonistic LPS aggravates systemic
autoimmunity and LN [7].
Using transgenic mouse called TCr-5, whose genome
contains multiple copies of the tlr4 gene on a TLR4-
deficient C57/BL10ScCr (deletion of tlr4 gene and point
mutation in IL-12Rβ 2gene) background, it has been
shown that up-regulation TLR4 is pathogenic both at the
protein level and gene level and triggered spontaneous
SLE-like autoimmunity and lupus nephritis [8]. Mice defi-
cient in Lyn, a serin threonine kinase with an inhibitory
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function on TLR4/IL-1 signaling in dendritic cells, develop
spontaneous lymphoproliferation, nephritis and autoanti-
body production. Indeed, the effects of Lyn-deficiency
could be restored by simultaneous deletion of MyD88 in
dendritic cells [9]. Obviously, the immunostimulatory func-
tions of TLR4 can trigger the initiation of autoimmunity in
permissive genetic constellations [10] even when aberrant
TLR-4/IL-1 signaling is restricted only to dendritic cells [9].
However, Tlr2 or − 4-deficiency in MRL/lpr mice did not
significantly affect disease severity [11].
In human overt SLE, TLR2 mRNA is upregulated in
PBMCs [12] but in young lupus patients (median age of
13 years at the time of enrolment) monocyte TLR2 and-4
cell surface expression can be even reduced when examined
by flow cytometry [13]. Stimulation of PBMCs from SLE
patients with TLR2 or − 4 agonists triggers more cytokine
production as compared to healthy subjects [14]. TLR2 is
also increased on CD4+ and CD8+ positive T cells and
B cells from SLE patients, which is associated with the
increased in-vitro production of IL-17 upon activation
with TLR-2 agonists [15]. South Indians bearing the
TLR4 promoter polymorphisms D299G and T399I show
an increased risk for specific autoantibody production
(Table 1) [16]. Together, accumulating data suggest an
involvement of TLR2 and − 4 in the pathogenesis of
systemic autoimmunity in mice and humans.
Toll-like receptor-5
Little is known about TLR5 in lupus but some contribu-
tion to SLE seems possible. Renal TLR5 expression is
upregulated in nephritic MRL/lpr mice, probably because
of immune cell infiltrates. In vitro treatment of murine
macrophages with the TLR5 ligand flagellin induces IL-6
production [17] indicating that microbial components can
efficiently ligate with activated immune cells present in
immune complex glomerulonephritis. In humans, TLR5
maps to a q41-q42 locus on chromosome 1 that includes
strong SLE susceptibility genes. Transmission disequilibrium
testing in a cohort of 199 SLE patients versus 75 healthy
siblings implies a protective role for SNP1174T in the TLR5
gene, probably because SNP1174T transmits a stop codon
abrogating TLR5 signaling [18]. The rs5744168 is most
studied SNP for TLR5 and found no genotype-phenotype
association in SLE however, the Tallele and the TTgenotype
Fig. 1 Toll-like receptor (TLR) signalling pathways. TLR1, TLR2, TLR4, TLR5, TLR6, TLR11, TLR12 as homo or heterodimers bind to their respective
ligands at the cell surface, whereas TLR3, TLR7/TLR8, TLR9, and TLR13 sense nucleic acids in endosomes. TLR4 localizes at both the plasma
membrane and the endosomes. The Toll–IL-1-resistence (TIR) domains of TLRs-dimers bind TIR domain-containing adaptor proteins (either myeloid
differentiation primary-response protein 88 (MYD88), or TIR domain-containing adaptor protein inducing IFNβ (TRIF) and TRIF-related adaptor molecule
(TRAM)). Downstream signalling pathways of TLRs involve IL-1R-associated kinases (IRAKs), IκB kinase -alpha, beta, gamma and epsilon (IKK αβγε-) and
the adaptor molecules TNF receptor-associated factors (TRAFs). These protein complexes activate p50 and p65, as well as various transcription factors
such as interferon-regulatory factors (IRFs) and activator protein 1 (AP1). TLR signalling leads to the induction of pro-inflammatory cytokines or the
induction of type I interferon (IFN)
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were raised significantly in LN patients group indicating the
putative role of TLR5 in the progression of LN [19]. Even
though the available data on TLR5 with respect to SLE are




TLR3 receptor localizes to intracellular endosomes and
senses double-stranded RNA via the adaptor TRIF instead
of MyD88 [20]. This way TLR3 employs the transcription
factor IRF3 to induce type I interferon secretion, a central
element in the pathogenesis of SLE [10]. Although single
vaccination-like doses of the TLR3 ligand polyI:C RNA do
not exacerbate autoimmunity in MRL/lpr or FcγR2b−/−
mice with SLE-like autoimmunity, repetitive doses of
polyI:C RNA do aggravate kidney disease in MRL/lpr mice
but independently from B cell-driven immune complex
disease [21, 22]. It, therefore, was concluded that viral
dsRNA triggers disease activity of lupus nephritis by
mechanisms that are different from those of bacterial
DNA. The gene product of the ITGAM gene, CD11b, is
an endogenous negative regulator of TLR3 signaling and
gene variants in the ITGAM gene affect the risk for SLE
in humans [23] suggesting activation of CD11b could be a
potential mechanism for developing SLE therapeutics.
In SLE patients also TLR3 expression is upregulated in
total PBMCs, T- and B cells [24, 25]. The TLR3 gene
rs3775296-T risk allele was found to be associated with
anaemia and photosensitivity in Taiwanese SLE patients [26]
indicating that TLR3 involved the development of different
SLE phenotypes, and in antiviral responses that trigger
expression of pro-inflammatory genes. Taken together
these data suggest that viral ds RNA trigger disease activity
through TLR3 in a MyD88 independent pathway involving
various innate immune cells.
Table 1 Various TLR polymorphisms studied in SLE and LN patients
TLR Allele Ethnicity/year of study Association
TLR2 rs1816702,rs4235232 multiethnic group,2014 positive [149]
R753Q South Indians,2015 positive [150]
TLR3 rs3775296-T Taiwanese,2014 positive [26]
rs3775291 Danish,2014 positive [151]
rs3775291 Meta analysis, 2016 No association [60]
TLR4 D299G,T399I Meta analysis 2016 positive [152]
rs4986790,rs4986791 Meta analysis, 2016 No association [60]
D299G,T399I South Indian cohort,2015 positive [16]
1196 C/T Polish population,2013 Negative [153]
TLR5 rs5744168 Americana,2017 No association [19]
rs5744168 Zhuang and Han ethnics,2015 No association [154]
TLR7 PTPN22 Variant R620W Americana,2015 positive [155]
rs3853839 Danish,2014 positive [156]
s3853839-G,rs3853839,rs179010-T Taiwanese,2014 positive [26]
rs3853839 Mutliethnic group,2013 positive [157]
TLR8 rs3764880-G,rs3764880 Taiwanese,2014 positive [26]
rs3764879 Danish,2014 positive [156]
rs37648 Danish,2014 positive [151]
TLR9 rs352143 Danish,2014 positive [151]
rs352140 Americana,2017 positive [19]
rs352140 Zhuang and Han ethnics,2015 positive [154]
PTPN22 rs2476601 Meta analysis,2017 positive [158]
rs187084 South Indians,2017 positive [159]
rs352139 Egyptian,2016 positive [160]
-1237C/T South Indians,2015 positive [150]
T-1237C and T-1486C Meta analysis,2013 negative [161]
rs352140, rs5743836,rs352139 Meta analysis, 2016 negative [60]
aethnicity was not clear; study information was restricted for the last five years
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Toll-like receptor-7
TLR7 locates together with TLR3 (and TLR9) inside intra-
cellular endosomes. TLR7 senses viral single-stranded RNAs
and triggers cytokine and type I interferon production for
antiviral host defense but endogenous nucleic acids can have
the same effect [27, 28]. TLR7 activation with imiquimod
activates systemic type I interferon production and aggra-
vates lupus nephritis in MRL/lpr mice [29]. Monoclonal
antibodies targeting TLR7 get internalized after binding to a
surface-bound TLR7 fraction [30]. TLR7 activity mediates
the formation of anti-RNA autoantibodies and glomerulo-
nephritis in MRL/lpr mice as well as in pristane-induced
SLE [31, 32]. MRL/lpr mice deficient for TLR7- and TLR9-
signalling do not develop antinuclear antibodies [33]. TLR9
activity inhibits TLR7-mediated autoimmunity [33]. There-
fore, MRL/lpr mice lacking TLR9 develop increased
autoantibody levels directed against RNA autoantigens
such as anti-Sm or anti-ribosomal P Ag [33].
TLR7 overexpression in B6.yaa mice illustrates that
increased TLR7 activity alone is not sufficient to trigger
autoimmunity without gene variants in other susceptibility
genes [34]. The y-linked autoimmune accelerator (yaa)
allele is the most potent disease allele on the Y chromosome
detected in BXSB mouse strain involved in the pathogenesis
of lupus nephritis; however, yaa could produce disease only
when combined with other autoimmune promoting genes
[35, 36].TLR7-driven type I interferon secretion can also
promote hematopoietic abnormalities [37]. TLR3/TLR7
co-activation has synergistic immunostimulatory effects
in MRL/lpr mice [38].
TLR7 is expressed in several B cell subtypes, macro-
phages, and plasmacytoid dendritic cells [39]. In MRL/lpr
mice dendritic cells promote expansion and differentiation
of T cells, but not their activation [40]. Interestingly, in
MRL/lpr mice TLR/MyD88 signaling in dendritic cells is
dispensable for the development of autoantibody produc-
tion and lupus nephritis [41]. TREML4 augments TLR7
signaling during autoimmune disease. Indeed, Treml4-
deficient MRL/lpr mice have reduced T cell numbers,
lower systemic IFN-α levels, show less nephritis [42].
Mice, lacking the negative regulator Lyn, spontaneously
develop autoimmunity [43] and conditional deletion of
MyD88 in dendritic cells in Lyn-deficient mice decreases
germinal center formation, DNA autoantibody produc-
tion, and immune complex glomerulonephritis [44]. A
similar phenotype is present in mice deficient for the
negative regulator interleukin-1 receptor-associated
kinase-M [45] and single Ig IL-1-related receptor [46]. In
addition, abolishing the function of plasmacytoid dendritic
cells in TLR7.Tg mice, a model of TLR7-driven auto-
immunity, attenuated glomerular immune complex de-
posits and prolonged lifespan of the mice [47].
In contrast, genetic depletion of MyD88 in B cells impairs
the secretion of antinuclear antibodies and abrogates lupus
nephritis because activated B cells contribute to both
antibody-dependent and -independent renal T cell infil-
trates in MRL/lpr mice [41]. Indeed, in Tlr7 transgenic
mice autophagy in B cells is an initiating event triggering
TLR7-dependent autoantibody production [48]. B cell
receptor-driven uptake of immune complexes stimulates
TLR7 and − 9 inside B cells and drives RNA- and DNA-
autoantibody production, respectively [33, 49–54]. In this
context, germinal center formation in health and disease
involves B cell TLR7 signaling [55]. Thus, normalizing
CD19+ B cell TLR7 expression in transgenic Tg7Sle1B6
mice overexpressing TLR7 in a lupus-prone background
normalized lymphocyte activation but not proliferation.
Nevertheless, less production of RNA autoantibodies
somewhat reduced the activity of immune complex
glomerulonephritis [56].
PBMCs from different ethnic SLE populations consistently
overexpress TLR7 along with a type I interferon transcript
signature [57, 58]. TLR7 gene variants can be risk factors for
human SLE [26, 59]. A recent meta-analysis comprising
11,984 patients documented a link between the TLR7 vari-
ants rs179008 and the risk of SLE in African populations
and between rs3853839 and SLE in Asians [60]. Japanese
male SLE patients carrying a single nucleotide poly-
morphism in the 3’UTR of the TLR7 gene corresponds
to an increased TLR7 gene dose and type-I interferon
gene signature [61]. Furthermore, a Mexican case-control
study of 328 childhood-onset SLE patients and 403 con-
trols displayed an increase in TLR7 copy numbers as an
SLE risk factor [62]. It is of note that, another study could
not confirm these in adult-onset SLE [63]. Interestingly,
the gene product of the ITGAM gene, CD11b, is an
endogenous negative regulator of TLR7 signaling and gene
variants in the ITGAM gene affect the risk for SLE in
humans [23]. Intrinsic IgE seems to be another en-
dogenous inhibitor of TLR7-mediated IFN-α induction
in dendritic cells isolated from SLE patients [64]. In
summary, TLR7 is involved in the pathogenesis of murine
and human SLE and LN by sensing endogenous ribonu-
cleoprotein antigens for the activation of antigen presenting
cells such as B cells and dendritic cells [10, 65, 66]. In this
process, the nucleic acid component acts as an endogenous
adjuvant to boost immunity against ribonucleoproteins
[67]. The phenomenon of TLR7 sensing danger signals of
RNA autoantigens is similar to sensing signals delivered
during viral infection and could therefore be referred to as
molecular mimicry in innate immunity.
Toll-like receptor-8
In humans, TLR8 senses ssRNA [68–70] but its role in
autoimmunity is less clear. 564Igi mice, a knock-in strain
expressing an autoreactive anti-RNA-antibody, require
TLR8 and MyD88 to break tolerance and to induce a
type-I interferon signature [71]. Autoantibody secretion
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is abrogated upon simultaneous deletion of TLR7 and
TLR8 but not of TLR7 and TLR9 or other combinations
[71]. However, TLR8 deletion of C57BL/6 genetic back-
ground triggers anti-dsDNA antibody secretion and glom-
erulonephritis, an effect abrogated by co-deletion of TLR7
suggesting rather an immunoregulatory role of TLR8 in
TLR7 [72]. Indeed, dendritic cells isolated from Tlr8−/−
mice present increased TLR7 expression and are hyper-
responsive to TLR7 agonists [72]. In contrast to TLR9,
which mainly executes its regulatory effect on TLR7 in
B cells, TLR8 inhibits TLR7 mostly in dendritic cells
[10, 73]. Evidently, TLR9 and TLR8 inhibit TLR7-mediated
autoimmunity and renal inflammation in a synergistic
manner [71, 73].
TLR8 is also present in humans [26, 74, 75] and TLR8
expression levels are upregulated in blood cells of paediatric
and adult lupus patients [76]. Females express higher levels
of TLR8 mRNA in blood cells in the presence of 17β-
estradiol as a potential factor in gender disparity of SLE
[74]. In addition, the TLR8 single nucleotide polymorphism
rs3764880 is associated with an increased risk for SLE in
females but not in males [26]. As another aspect, certain
antiphospholipid antibodies upregulate miR-146a-3p in
trophoblast cells, which enhances TLR8-mediated IL-8-
secretion [75]. Together, also TLR8 seems to have an
immunoregulatory role in systemic autoimmunity, espe-
cially in females.
Toll-like receptor-9
AlsoTLR9 localizes to the endosomal compartment
where it senses unmethylated CpG motifs in the DNA
sequence of viruses or bacteria [10]. However, endogenous
TLR9 ligands exist, e.g. hypomethylated self-DNA within
immune complexes, neutrophil extracellular traps, oxi-
dized mitochondrial nucleoids or other chromatin formats
[10, 28, 77–79]. Defects in lysosomal maturation endorse
the activation of TLR9 [80]. TLR9 ligation is followed by
type I interferon production in immune cells especially
plasmacytoid dendritic cells [81]. Indeed, TLR9 and TLR7
in SLE partially mimic a state of anti-viral host defense
referred to as “pseudoantiviral immunity” [82, 83]. Type I
interferons promote the responsiveness to B-cell receptor
crosslinking in B cells and render dendritic cells respon-
sive to endogenous nucleic acids after upregulation of
TLR7 and TLR9 [84, 85]. TLR9-dependent type I inter-
feron production depends on a lipid kinase - PIKfyve, a
mechanism that can neutralized by apilimod [86]. How-
ever, not all features of human SLE are attributable to type
I Interferons as longitudinal studies do not always show I
interferon signatures to indicate disease activity in patients
[87, 88]. Blocking endogenous TLR9 ligands with a TLR9
antagonist in MRL/lpr mice ameliorated systemic auto-
immunity and immune complex glomerulonephritis [89].
Consistently, injections with CpG and LPS to anti-dsDNA
transgenic mice exacerbated disease [7]. In line, Tlr9-
deficient C57BL/6 mice display less autoimmunity and
nephritis due to less glomerular Ig-deposits and comple-
ment activation in pristane-induced autoimmunity [6].
However, BALB/c mice injected with pristane show differ-
ent effects, highlighting the contribution of additional
genetic factors [90]. Nevertheless, dual inhibition of both
TLR7 and TLR9 did not elicit additive effects beyond single
blockade of TLR7 in MRL/lpr mice. TLR9 inhibition even
neutralized the beneficial effects of the TLR7 blockade on
systemic autoantibody levels without affecting the effects of
the TLR7 blockade on nephritis [91]. Hence, the regulatory
role of TLR9 is context-dependent.
It is of note that TLR9 deletion in MRL/lpr mice
aggravates systemic autoimmunity and immune complex
glomerulonephritis, a phenomenon that can be neutralized
co-deletion of TLR7 [33]. Obviously, TLR9 and TLR7
normally compete for endosomal trafficking implying
that increased TLR7 signaling driving autoimmunity
can outweigh the pro-inflammatory effects of TLR9
[92, 93]. In addition, Tlr9- and Tlr8-double-deficient
C57BL/6 mice develop spontaneous signs of autoimmunity
such as splenomegaly, autoantibody production, and glom-
erulonephritis. Here, TLR9 seems to restrict B cell TLR7
signaling, while TLR8 suppresses TLR7-driven activation
of dendritic cells [73]. However, B cell TLR9 is required for
the generation of DNA antibodies in mice and promotes
the differentiation of autoantibody-secreting B and plasma
cells in humans [94, 95]. TLR9 mRNA expression is also
upregulated in PBMCs from SLE patients, correlates with
lupus nephritis [57, 96], and correlates with circulating
anti-DNA autoantibody levels [96]. B cell TLR9 expression
is associated with serum creatinine levels in SLE patients
[25]. Intrinsic IgE inhibits also TLR9-mediated IFN-α
induction in dendritic cells isolated from SLE patients [64].
Together, TLR has a complex role in SLE as it promotes
DNA autoantibody production as an important compo-
nent of lupus nephritis. However, TLR9 also inhibits TLR7
signaling as another central pathway in the pathogenesis of
SLE. Therefore, therapeutic TLR9 inhibition may cause
unexpected effects in human SLE depending on the
predominant role of these different elements of disease
pathogenesis.
Toll-like receptors inside the nephritic kidney
How do TLRs maintain tissue inflammation inside the
kidney once lupus nephritis has established? Extrinsic
and intrinsic ligands can ligate TLRs on infiltrating
monocytes, dendritic cells and B cells to enhance cyto-
kine secretion [17, 97, 98]. Furthermore, mesangial cells
and other parenchymal cells express TLR1–4, and TLR6
[17]. In culture, renal cells respond to TLR activation
and secrete interleukins and chemokines [17, 99]. Also,
immune complex deposits containing TLR agonists
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activate glomerular mesangial cells and contribute to
immune complex glomerulonephritis [100, 101].
Inside the kidney, TLR2 and TLR4 are expressed not
only by parenchymal cells but also by infiltrating neutro-
phils and mononuclear phagocytes including macrophages
and dendritic cells [10, 102]. Murine macrophages respond
to TLR2 and − 4 agonists by secretion of pro-inflammatory
cytokines [17]. Also, HMGB1, a DNA-binding protein, and
lupus autoantigen, released under inflammatory conditions
can induce NF-κB activation in a TLR2 and TLR4-RAGE-
dependent manner in mononuclear phagocytes and
neutrophils [103, 104] as well as in mesangial cells
[103, 105]. When HMGB1 combines with the nephrito-
genic anti-DNA antibody 1A3F they form complexes that
activate the TLR2 axis in mesangial cells via the FoxO1
signaling pathway [83, 105, 106]. Mesangial cells and
podocytes express also TLR4 in the nephritic environment
[17, 107]. Mesangial cells isolated from NZB/W mice
with spontaneous autoimmunity express significantly
higher levels of TLR4 and produce significantly more
pro-inflammatory chemokines under baseline and LPS-
stimulated conditions [108]. Also, necrotic cell debris is
enriched with endogenous TLR ligands that stimulate
cytokine release via TLR2/MyD88 depend on the way
in mesangial cells, a finding that probably implies also
to other intrarenal cell types expressing TLR2 [109].
Intrarenal TLR2 and TLR4 expression are also enhanced in
kidneys from FcgammaRIIb-deficient mice suffering from
cryoglobulinemic glomerulonephritis [107]. In MRL/lpr
mice bacterial lipopeptide aggravates albuminuria in
nephritic animals via TLR2-mediated activation of podo-
cytes and endothelial cells at the glomerular filtration
barrier [110]. These data help to understand how TLR2
and − 4 on infiltrating immune cells and parenchymal cells
amplify local inflammation and barrier dysfunction by
sensing extrinsic and intrinsic danger signals serving as
TLR agonists.
An inflammatory microenvironment stimulates TLR3
expression in murine and human mesangial cells [17, 111].
Repetitive injections with the TLR3 agonist poly I:C RNA
aggravates glomerulonephritis in MRL/lpr mice without
affecting systemic autoantibody levels, hence, circulating
viral double-stranded promote lupus nephritis mainly via
local cytokine production by infiltrating macrophages and
resident renal mesangial cells [22]. It is of note that mesan-
gial cells from female animals express more TLR3 copies
and secrete more IL-6 production upon TLR3 activation,
providing another explanation for gender disparity in
lupus. Indeed, deficiency of estrogen receptor-α in mesan-
gial cells abrogates TLR3 signaling in mesangial cells [112].
Also, chloroquine attenuates TLR3-mediated type I inter-
feron induction in human mesangial cells [113, 114]. TLR3
ligation in human mesangial cells promotes the secretion
of the neutrophil chemoattractant CXCL1 and CXCL1 is
also expressed in diagnostic biopsies from patients with
lupus nephritis but not in biopsies of patients with IgA
nephropathy [99]. These data support the concept of
pseudo-antiviral immunity also at the tissue level because
type I interferons from resident renal cells drive renal
damage in experimental antibody-triggered glomerulo-
nephritis [98, 114, 115]. Tubuloreticular inclusions repre-
sent a morphological imprint of local type I interferon
activity and can be found only in lupus nephritis, viral
nephropathies, and upon IFN-α treatment [116]. It is of
note that type I interferon production in mesangial cells
does not require TRIF or MyD88 when it involves non-
TLR cytosolic RNA recognition receptors [117, 118].
In murine and human lupus nephritis plasmacytoid
dendritic cells type recognize ssRNA, CpG DNA from
bacteria and viruses as well as altered eucaryotic nucleic
acids via TLR7 and − 9 [119], which induces the release of
type I interferons and foster local and systemic immune
responses via enhanced expression of costimulatory
molecules [116, 119]. Specific deletion of plasmacytoid
dendritic cells in a murine TLR7-driven lupus model
(Tlr7.Tg) or a polygenic model (B6.Sle1.Sle3) attenuates
not only systemic autoimmunity but also lupus nephritis
[47]. Transient depletion of plasmacytoid dendritic cells
can somewhat suppress glomerulonephritis [120]. Also,
conventional dendritic cells express TLR7 in Sle1Tg7 mice.
TLR7 overexpression is associated with an accumulation
of CD11b + conventional dendritic cells inside the kidneys.
Correcting the abnormal expression levels of TLR7 select-
ively in CD11c + conventional dendritic cells protected
kidneys from autoimmune inflammation [39]. Thus,
TLR7-mediated RNA sensing in conventional dendritic
cells is an essential component in lupus nephritis in mice
[39]. Similar studies were conducted to evaluate the
alterations in circulating or possibly tissue infiltrating
DCs in human lupus nephritis patients and found that
conventional and plasmacytoid dendritic cells decreased
in circulation enriched in both, the glomerular and tubu-
lointerstitial, compartments in diagnostic kidney biopsies
of SLE patients with lupus nephritis suggesting locally
recruited DCs might play a pathogenic role in LN [121].
Circulating nucleic acids inside immune complexes can
ligate TLR9 inside antigen-presenting cells (mononuclear
phagocytes and B cells) to trigger pro-inflammatory cyto-
kines as well as antibody secretion [10, 17]. TLR9 is absent
in mesangial cells of MRL/lpr mice but other groups
found TLR9 in tubular epithelial cells of NZBxNZW mice
and in diagnostic biopsies of patients with lupus nephritis
[17, 122–124]. In childhood-onset lupus nephritis injured
podocytes stained positive for TLR9, while TLR9 was
absent in podocytes of healthy control kidneys or during
remission of lupus nephritis [125, 126]. BXSB-Yaa mice
with SLE express TLR8 mRNA and protein in podocytes
and TLR8 expression was found to correlate with podocyte
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injury and negatively correlate with albuminuria [127].
Overall, TLR7, − 8, and 9 drive lupus nephritis because
endogenous (and during infections possibly exogenous)
nucleic acid-based TLR agonists activate infiltrating
antigen-presenting cells inside the nephritic kidney.
TLRs in immune tolerance break and germinal center
formation
Other aspects of TLR involvement in autoimmune diseases
are immune tolerance and germinal centers formation.
Here we would like to provide readers a brief summary of
these two aspects. Failure or loss of central and peripheral
immune system results in the uncontrolled activation of
self-reactive B and Tcells and hence results in autoimmun-
ity. Different TLRs have been shown to involve in this
breakdown of tolerance [128–130]. For example, repeated
stimulation of TLRs induces unresponsiveness to the same
TLR ligand in cell lines [131, 132], B cells [133] and
plasmacytoid DCs [134, 135].In some observations, it
was found that repeated stimulation of a specific TLR
can even result in cross-tolerance but also in enhanced
responsiveness to other specific TLR ligands [131].This
discrepancy might be due to differences in the hetero-
geneity and activation status of target cells [132].
Various TLRs expressed on B cells are not only capable
of promoting antibody responses in the absence of T cells
help [136, 137], but also promote germinal center (GC)
responses very strongly [137–140].TLRs promote GC
formation in an antigen oligomerization degree dependent
manner [141](82). For example, viral particles with high
oligomerized antigen proteins stimulate GC formation
using TLR7 or TLR9, this response could be speculated as
an adaptive mechanism to promote the generation of
protective antibodies against viral infections [141].The
TLR7 intrinsic expression is required for effective GC
response to generate neutralizing antibodies against
Friend virus as retrovirus [142] or LCMV clone 13 [143,
144].Therefore TLRs ability to promote GC formation
evolved as a protective mechanism against viral infections
however this could also promote lupus-like autoantibodies
in a genetically susceptible background [140].
Conclusion
SLE is a consequence of genetic variants that promote a
loss-of-tolerance and systemic autoimmunity against
nuclear autoantigens. Half of the SLE patients suffer
from some sort of renal involvement. Endogenous nucleic
acids do not only serve as autoantigens but also as auto-
adjuvants in the pathogenesis of lupus and lupus nephritis
because they drive the activation of antigen-presenting
cells, and type I interferon release, and consequently
adaptive immunity and immune complex disease, e.g.
lupus nephritis. Targeting these mechanisms is possible
in several ways: 1) avoiding cell death, e.g. sunburns by
applying sunscreens, 2) avoiding drugs that endorse
hypomethylation of endogenous nucleic acids, e.g. dihy-
dralazine, 3) scavenging nucleic acid debris [145], 4)
blocking TLR activation with chloroquine or more specific
endosomal TLR antagonists, 5) blocking co-stimulation or
6) blocking type I interferon signaling [146, 147]. Other
endogenous triggers of innate immunity activate TLRs on
also renal parenchymal cells, e.g. TLR3 in mesangial cells
or TLR2 and TLR4 on endothelial cells and podocytes at
the glomerular filtration barrier [148]. Altogether, TLRs
elicit major contributions to the pathogenesis of SLE and
lupus nephritis and their associated pathways remain
attractive targets for therapeutic interventions.
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